TOXICITY AND EFFICACY OF LOMUSTINE PLUS BEVACIZUMAB IN RECURRENT GLIOBLASTOMA PATIENTS

被引：0
|
作者：
Jakobsen, Jan Nyrop [1 ]
Urup, Thomas [1 ]
Grunnet, Kirsten [1 ,2 ]
Christensen, Ib Jarle [3 ]
Villingshoj, Mette [2 ]
Poulsen, Hans Skovgaard [1 ,2 ]
机构：
[1] Rigshosp, Dept Oncol, Copenhagen, Denmark
[2] Rigshosp, Dept Radiat Biol, Copenhagen, Denmark
[3] Univ Copenhagen, Hvidovre Hosp, Lab Gastroenterol, Copenhagen, Denmark
来源：
NEURO-ONCOLOGY | 2017年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
ACTR-26
引用
收藏
页码：6 / 6
页数：1
相关论文
共 50 条
  • [41] Comparative Efficacy of Bevacizumab and PCV Chemotherapy in Recurrent Glioblastoma
    Dixit, S.
    Hingorani, M.
    [J]. CLINICAL ONCOLOGY, 2015, 27 (04) : 246 - 247
  • [42] PHASE II AND BIOMARKER STUDY OF PEMBROLIZUMAB OR PEMBROLIZUMAB PLUS BEVACIZUMAB FOR RECURRENT GLIOBLASTOMA PATIENTS
    Reardon, David
    Molinaro, Annette
    Peters, Katherine
    Clarke, Jennifer
    Jordan, Justin
    de Groot, John
    Nghiemphu, Phioanh
    Kaley, Thomas
    Colman, Howard
    McCluskey, Christine
    Smith, Timothy
    Cote, David
    Severgnini, Mariano
    Yearley, Jennifer
    Zhao, Qing
    Blumenschein, Wendy
    Duda, Gabriel
    Muzikansky, Alona
    Jain, Rakesh
    Wen, Patrick
    Nayak, Lakshmi
    [J]. NEURO-ONCOLOGY, 2020, 22 : 40 - 40
  • [43] Phase II study of pembrolizumab or pembrolizumab plus bevacizumab for recurrent glioblastoma (rGBM) patients
    Reardon, David A.
    Nayak, Lakshmi
    Peters, Katherine B.
    Clarke, Jennifer Leigh
    Jordan, Justin T.
    De Groot, John Frederick
    Nghiemphu, Phioanh Leia
    Kaley, Thomas Joseph
    Colman, Howard
    Gaffey, Sarah C.
    Caruso, Victoria
    Debruyne, Myriam Bednarek
    Bhavsar, Chinmay
    Molinaro, Annette M.
    Smith, Timothy
    Severgnini, Mariano
    Wen, Patrick Y.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [44] A phase II study of feasibility and toxicity of bevacizumab in combination with temozolomide in patients with recurrent glioblastoma
    Sepulveda, J. M.
    Belda-Iniesta, C.
    Gil-Gil, M.
    Perez-Segura, P.
    Berrocal, A.
    Reynes, G.
    Gallego, O.
    Capellades, J.
    Ordonez, J. M.
    La Orden, B.
    Balana, C.
    [J]. CLINICAL & TRANSLATIONAL ONCOLOGY, 2015, 17 (09): : 743 - 750
  • [45] A phase II study of feasibility and toxicity of bevacizumab in combination with temozolomide in patients with recurrent glioblastoma
    J. M. Sepúlveda
    C. Belda-Iniesta
    M. Gil-Gil
    P. Pérez-Segura
    A. Berrocal
    G. Reynés
    O. Gallego
    J. Capellades
    J. M. Ordoñez
    B. La Orden
    C. Balañá
    [J]. Clinical and Translational Oncology, 2015, 17 : 743 - 750
  • [46] Bevacizumab Alone Versus Bevacizumab Plus Irinotecan in Patients With Recurrent Glioblastoma: A Nationwide Population-Based Study
    Lee, Yeonhu
    Lee, Eunyoung
    Roh, Tae Hoon
    Kim, Se-Hyuk
    [J]. JOURNAL OF KOREAN MEDICAL SCIENCE, 2024, 39 (34)
  • [47] BEVACIZUMAB ALONE VERSUS BEVACIZUMAB PLUS IRINOTECAN IN PATIENTS WITH RECURRENT GLIOBLASTOMA: A NATIONWIDE POPULATION-BASED STUDY
    Lee, Yeonhu
    Roh, Tae Hoon
    Kim, Se-Hyuk
    [J]. NEURO-ONCOLOGY, 2023, 25
  • [48] BEVACIZUMAB ALONE VERSUS BEVACIZUMAB PLUS IRINOTECAN IN PATIENTS WITH RECURRENT GLIOBLASTOMA: A NATIONWIDE POPULATION-BASED STUDY
    Lee, Yeonhu
    Roh, Tae Hoon
    Kim, Se-Hyuk
    [J]. NEURO-ONCOLOGY, 2023, 25
  • [49] Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma
    Xu, Qingsheng
    Huang, Kaiyuan
    Meng, Xiangqi
    Weng, Yuxiang
    Zhang, Luyuan
    Bu, Linghao
    Zheng, Xiujue
    Cai, Jinquan
    Zhan, Renya
    Chen, Qun
    [J]. CLINICAL CANCER RESEARCH, 2023, 29 (19) : 3859 - 3866
  • [50] BEVACIZUMAB AND IRINOTECAN IN THE TREATMENT OF PATIENTS WITH RECURRENT GLIOBLASTOMA
    Naskhletashvili, D. R.
    Gorbounova, V.
    Bychkov, M.
    Bekyashev, A.
    Karakhan, V.
    Aloshin, V.
    Fu, R.
    Moskvina, E.
    [J]. NEURO-ONCOLOGY, 2012, 14 : 59 - 59
12345